company background image
BLUE logo

bluebird bio NasdaqGS:BLUE Stock Report

Last Price

US$1.10

Market Cap

US$212.0m

7D

-10.6%

1Y

-64.7%

Updated

14 Apr, 2024

Data

Company Financials +

bluebird bio, Inc.

NasdaqGS:BLUE Stock Report

Market Cap: US$212.0m

bluebird bio, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for bluebird bio
Historical stock prices
Current Share PriceUS$1.10
52 Week HighUS$5.53
52 Week LowUS$0.88
Beta0.80
1 Month Change-22.54%
3 Month Change-26.67%
1 Year Change-64.74%
3 Year Change-96.11%
5 Year Change-99.20%
Change since IPO-95.91%

Recent News & Updates

bluebird bio Is Priced Below IP Value

Mar 23

Bluebird Bio: Innovative Therapies, Monetary Setbacks

Jan 25

Recent updates

bluebird bio Is Priced Below IP Value

Mar 23

Bluebird Bio: Innovative Therapies, Monetary Setbacks

Jan 25

Is bluebird bio (NASDAQ:BLUE) In A Good Position To Invest In Growth?

Oct 13
Is bluebird bio (NASDAQ:BLUE) In A Good Position To Invest In Growth?

Here's Why We're A Bit Worried About bluebird bio's (NASDAQ:BLUE) Cash Burn Situation

Jul 13
Here's Why We're A Bit Worried About bluebird bio's (NASDAQ:BLUE) Cash Burn Situation

Bluebird, Real Endpoints team up to increase access to pricey gene therapy Zynteglo

Oct 04

Bluebird bio names interim finance chief

Sep 26

Bluebird bio jumps 17% on FDA approval of new gene therapy

Sep 19

bluebird bio' chief strategy and financial officer to depart

Sep 12

FDA approves bluebird bio's Zyntego beti-cel gene therapy for beta thalassemia

Aug 17

bluebird bio: Potential For 3 Gene Therapy Approvals In 12 Months Makes Buy Case

Jun 22

bluebird bio: Beaten Down Biotech With Possible Long-Term Potential

May 09

Bluebird Bio: Gene Therapy Launches Could Bring Big Revenues, Providing They Meet Approval

Feb 07

bluebird bio: Ticker Fueled By Gambling Chance Of Commercial Success

Dec 12

bluebird bio (NASDAQ:BLUE) Will Have To Spend Its Cash Wisely

Nov 08
bluebird bio (NASDAQ:BLUE) Will Have To Spend Its Cash Wisely

bluebird bio: Like A Bird In The Middle Of The Deep Blue Sea

Nov 03

Shareholder Returns

BLUEUS BiotechsUS Market
7D-10.6%-2.9%-1.7%
1Y-64.7%-0.2%22.9%

Return vs Industry: BLUE underperformed the US Biotechs industry which returned -0.2% over the past year.

Return vs Market: BLUE underperformed the US Market which returned 22.9% over the past year.

Price Volatility

Is BLUE's price volatile compared to industry and market?
BLUE volatility
BLUE Average Weekly Movement15.8%
Biotechs Industry Average Movement11.6%
Market Average Movement6.1%
10% most volatile stocks in US Market16.6%
10% least volatile stocks in US Market3.0%

Stable Share Price: BLUE's share price has been volatile over the past 3 months.

Volatility Over Time: BLUE's weekly volatility (16%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
1992323Andrew Obenshainwww.bluebirdbio.com

bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy. The company’s clinical development programs include HGB-205, HGB-206, and HGB-210 to evaluate the safety and efficacy of lovo-cel in the treatment of patients with SCD; and HGB-204, HGB-205, HGB-207, and HGB-212 to evaluate the safety and efficacy of beti-cel in the treatment of patients with ß-thalassemia.

bluebird bio, Inc. Fundamentals Summary

How do bluebird bio's earnings and revenue compare to its market cap?
BLUE fundamental statistics
Market capUS$212.02m
Earnings (TTM)-US$91.17m
Revenue (TTM)US$21.73m

9.8x

P/S Ratio

-2.3x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
BLUE income statement (TTM)
RevenueUS$21.73m
Cost of RevenueUS$255.71m
Gross Profit-US$233.98m
Other Expenses-US$142.81m
Earnings-US$91.17m

Last Reported Earnings

Sep 30, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-0.47
Gross Margin-1,076.97%
Net Profit Margin-419.62%
Debt/Equity Ratio0%

How did BLUE perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.